 |
|
Intravitreal Triamcinolone in Diabetic Macular Edema—Reply
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
In reply
We would like to thank Mr Aslam and colleagues for their interest in our study.1 We agree that the follow-up was not complete, as at 9 months after the injection, data were available for only 8 patients. This incomplete follow-up is, without doubt, a limitation of the study. However, because the increase in visual acuity after an intravitreal injection of triamcinolone acetonide usually takes place within 4 weeks after the intervention and because the main purpose of the study was to assess factors associated with the increase in visual acuity, the loss of patients mainly at the end of follow-up might not have markedly influenced the conclusions drawn. We also agree with Mr Aslam and colleagues that the grading system of macula edema, such as the use of standard nonstereoscopic photographs, a single examiner, and the combination of the categories 0 to 2, 3 to 4, and 5 . . . [Full Text of this Article]
AUTHOR INFORMATION
Jost B. Jonas, MD;
Peter Martus, PhD;
Robert F. Degenring, MD;
Ingrid Kreissig, MD;
Imren Akkoyun, MD
RELATED ARTICLES
Intravitreal Triamcinolone in Diabetic Macular Edema
Sher Aslam, Nabeel Malik, and Nigel Davies
Arch Ophthalmol. 2006;124(10):1506-1507.
EXTRACT
| FULL TEXT
Predictive Factors for Visual Acuity After Intravitreal Triamcinolone Treatment for Diabetic Macular Edema
Jost B. Jonas, Peter Martus, Robert F. Degenring, Ingrid Kreissig, and Imren Akkoyun
Arch Ophthalmol. 2005;123(10):1338-1343.
ABSTRACT
| FULL TEXT
|
